The role of bisphosphonates in multiple myeloma

Current Hematologic Malignancy Reports

Volumn 4, Issue 2, 2009, Pages 108-112

  Levy, Jessica ^a   Roodman, David R ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; BORTEZOMIB; CLODRONIC ACID; DENOSUMAB; LENALIDOMIDE; PAMIDRONIC ACID; PLACEBO; ZOLEDRONIC ACID;

ANALGESIC ACTIVITY; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; BONE CANCER; BONE PAIN; CLINICAL TRIAL; DOSE KIDNEY FUNCTION RELATION; DRUG CLEARANCE; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; FATIGUE; FLU LIKE SYNDROME; HUMAN; IMMUNOMODULATION; JAW OSTEONECROSIS; LOW DRUG DOSE; MULTIPLE MYELOMA; MUSCULOSKELETAL DISEASE; NAUSEA; NEPHROTOXICITY; OSTEOCLAST; PHARMACOLOGICAL BLOCKING; QUALITY OF LIFE; REVIEW; SIDE EFFECT; TREATMENT INDICATION;

ANIMALS; BONE DENSITY CONSERVATION AGENTS; BONE DISEASES; DIPHOSPHONATES; DISEASE MODELS, ANIMAL; HUMANS; MULTIPLE MYELOMA; TREATMENT OUTCOME;

EID: 63549123413     PISSN: 15588211     EISSN: 1558822X     Source Type: Journal    
DOI: 10.1007/s11899-009-0015-4     Document Type: Review

References (50)

1. Coleman RE: Skeletal complications of malignancy. Cancer 1997, 80:1588-1594.
2. Melton LJ 3rd, Kyle RA, Achenbach SJ, et al.: Fracture risk with multiple myeloma: A population-based study. J Bone Miner Res 2005, 20:487-493.
3. Diamond T, Levy S, Day P, et al.: Biochemical, histomorphometric and densitometric changes in patients with multiple myeloma: Effects of glucocorticoid therapy and disease activity. Br J Haematol 1997, 97:641-648.
4. Berenson JR, Lichtenstein A, Porter L, et al.: Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. Myeloma Aredia Study Group. J Clin Oncol 1998, 16:593-602.
5. Yasuda H, Shima N, Nakagawa N, et al.: Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci U S A 1998, 95:3597-3602.
6. Hofbauer LC, Heufelder AE: OsteoprAtegerin and its cognate ligand: a new paradigm of osteoclastogenesis. Eur J Endocrinol 1998, 139:152-154.
7. Pearse RN, Sordillo EM, Yaccoby S, et al.: Multiple myeloma disrupts the TRANCE/osteoprotegerin cytokine axis to trigger bone destruction and promote tumor progression. Proc Natl Acad Sci U S A 2001, 98:11581-11586.
8. Sezer O, Heider U, Zavrski I, et al.: RANK ligand and osteoprotegerin in myeloma bone disease. Blood 2003, 101:2094-2098.
9. Lacey DL, Timms E, Tan HL, et al.: Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 1998, 93:165-176.
10. Terpos E, Szydlo R, Apperley JF, et al.: Soluble receptor activator of nuclear factor kappaB ligand-osteoprotegerin ratio predicts survival in multiple myeloma: Proposal for a novel prognostic index. Blood 2003, 102:1064-1069.
11. Han JH, Choi SJ, Kurihara N, et al.: Macrophage inflammatory protein-1alpha is an osteoclastogenic factor in myeloma that is independent of receptor activator of nuclear factor kappaB ligand. Blood 2001, 97:3349-3353.
12. Alsina M, Boyce B, Devlin RD, et al.: Development of an in vivo model of human multiple myeloma bone disease. Blood 1996, 87:1495-1501.
13. Choi SJ, Oba Y, Gazitt Y, et al.: Antisense inhibition of macrophage inflammatory protein 1-alpha blocks bone destruction in a model of myeloma bone disease. J Clin Invest 2001, 108:1833-1841.
14. Lee JW, Chung HY, Ehrlich LA, et al.: IL-3 expression by myeloma cells increases both osteoclast formation and growth of myeloma cells. Blood 2004, 103:2308-2315.
15. Roodman GD, Kurihara N, Ohsaki Y, et al.: Interleukin 6. A potential autocrine/paracrine factor in Paget's disease of bone. J Clin Invest 1992, 89:46-52.
16. Hjorth-Hansen H, Seifert MF, Borset M, et al.: Marked osteoblastopenia and reduced bone formation in a model of multiple myeloma bone disease in severe combined immunodeficiency mice. J Bone Miner Res 1999, 14:256-263.
17. Tian E, Zhan F, Walker R, et al.: The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. N Engl J Med 2003, 349:2483-2494.
18. Westendorf JJ, Kahler RA, Schroeder TM: Wnt signaling in osteoblasts and bone diseases. Gene 2004, 341:19-39.
19. Giuliani N, Morandi F, Tagliaferri S, et al.: Production of Wnt inhibitors by myeloma cells: Potential effects on canonical Wnt pathway in the bone microenvironment. Cancer Res 2007, 67:7665-7674.
20. Ehrlich LA, Chung HY, Ghobrial I, et al.: IL-3 is a potential inhibitor of osteoblast differentiation in multiple myeloma. Blood 2005, 106:1407-1414.
21. Giuliani N, Colla S, Morandi F, et al.: Myeloma cells block RUNX2/CBFA1 activity in human bone marrow osteoblast progenitors and inhibit osteoblast formation and differentiation. Blood 2005, 106:2472-2483.
22. Lee SK, Kalinowski JF, Jacquin C, et al.: Interleukin-7 influences osteoclast function in vivo but is not a critical factor in ovariectomy-induced bone loss. J Bone Miner Res 2006, 21:695-702.
23. Toraldo G, Roggia C, Qian WP, et al.: IL-7 induces bone loss in vivo by induction of receptor activator of nuclear factor kappa B ligand and tumor necrosis factor alpha from T cells. Proc Natl Acad Sci U S A 2003, 100:125-130.
24. Abe M, Hiura K, Wilde J, et al.: Osteoclasts enhance myeloma cell growth and survival via cell-cell contact: A vicious cycle between bone destruction and myeloma expansion. Blood 2004, 104:2484-2491.
25. Yaccoby S, Pearse RN, Johnson CL, et al.: Myeloma interacts with the bone marrow microenvironment to induce osteoclastogenesis and is dependent on osteoclast activity. Br J Haematol 2002, 116:278-290.
26. Croucher PI, Shipman CM, Van Camp B, Vanderkerken K: Bisphosphonates and osteoprotegerin as inhibitors of myeloma bone disease. Cancer 2003, 97:818-824.
27. Berenson JR, Lichtenstein A, Porter L, et al.: Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Myeloma Aredia Study Group. N Engl J Med 1996, 334:488-493.
28. McCloskey EV: Clodronate in the management of breast cancer and multiple myeloma. Ortop Traumatol Rehabil 2003, 5:227-233.
29. HeidenrIich A, Ohlmann CH: Ibandronate: its pharmacology and clinical efficacy in the management of tumor-induced hypercalcemia and metastatic bone disease. Expert Rev Anticancer Ther 2004, 4:991-1005.
30. Russell RG,AXia Z, Dunford JE, et al.: Bisphosphonates: an update on mechanisms of action and how these relate to clinical efficacy. Ann N Y Acad Sci 2007, 1117:209-257.
31. Galluzzo S, Santini D, Vincenzi B, et al.: Immunomodulating role of bisphosphonates on human gamma delta T cells: An intriguing and promising aspect of their antitumour activity. Expert Opin Ther Targets 2007, 11:941-954.
32. Shipman CM, Croucher PI, Russell RG, et al.: The bisphosphonate incadronate (YM175) causes apoptosis of human myeloma cells in vitro by inhibiting the mevalonate pathway. Cancer Res 1998, 58:5294-5297.
33. Gordon S, Helfrich MH, Sati HI, et al.: Pamidronate causes apoptosis of plasma cells in vivo in patients with multiple myeloma. Br J Haematol 2002, 119:475-483.
34. Arum SM: New developments surrounding the safety of bisphosphonates. Curr Opin Endocrinol Diabetes Obes 2008, 15:508-513.
35. Stewart GO, Stuckey BG, Ward LC, et al.: Iritis following intravenous pamidronate. Aust N Z J Med 1996, 26:414-415.
36. Coleman RE: Risks and benefits of bisphosphonates. Br J Cancer 2008, 98:1736-1740.
37. Badros A, Weikel D, Salama A, et al.: Osteonecrosis of the jaw in multiple myeloma patients: Clinical features and risk factors. J Clin Oncol 2006, 24:945-952.
38. Badros A, Evangelos T, Goloubeva O, et al.: Long-term follow-up of multiple myeloma (MM) patients (pts) with osteonecrosis of the jaw (ONJ) [poster]. Blood (ASH Annual Meeting Abstracts) 2007, 110:ABstract 3519.
39. Kyle RA, Yee GC, Somerfield MR, et al.: American Society of Clinical Oncology 2007 clinical practice guideline update on the role of bisphosphonates in multiple myeloma. J Clin Oncol 2007, 25:2464-2472.
40. Lacy MQ, Dispenzieri A, Gertz MA, et al.: Mayo Clinic consensus statement for the use of bisphosphonates in multiple myeloma. Mayo Clin Proc 2006, 81:1047-1053.
41. Khosla S, Burr D, Cauley J, et al.: Bisphosphonate-associated osteonecrosis of the jaw: Report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 2007, 22:1479-1491.
42. Vij R, Horvath N, Spencer A, et al.: An open-label, phase 2 trial of denosumab in the treatment of relapsed (R) or plateau-phase (PP) multiple myeloma (MM) [poster]. Blood (ASH Annual Meeting Abstracts) 2007, 110: Abstract 3604.
43. Mukherjee S, Raje N, Schoonmaker JA, et al.: Pharmacologic targeting of a stem/progenitor population in vivo is associated with enhanced bone regeneration in mice. J Clin Invest 2008, 118:491-504.
44. Oyajobi BO, Garrett IR, Gupta A, et al.: Stimulation of new bone formation by the proteasome inhibitor, bortezomib: Implications for myeloma bone disease. Br J Haematol 2007, 139:434-438.
45. Giuliani N, Morandi F, Tagliaferri S, et al.: The proteasome inhibitor bortezomib affects osteoblast differentiation in vitro and in vivo in multiple myeloma patients. Blood 2007, 110:334-338.
46. Terpos E, Heath DJ, Rahemtulla A, et al.: Bortezomib reduces serum dickkopf-1 and receptor activator of nuclear factor-kappaB ligand concentrations and normalises indices of bone remodelling in patients with relapsed multiple myeloma. Br J Haematol 2006, 135:688-692.
47. Anderson G, Gries M, Kurihara N, et al.: Thalidomide derivative CC-4047 inhibits osteoclast formation by downregulation of PU.1. Blood 2006, 107:3098-3105.
48. Breitkreutz I, Raab MS, Vallet S, et al.: Lenalidomide inhibits osteoclastogenesis, survival factors and boneremodeling markers in multiple myeloma. Leukemia 2008, 22:1925-1932.
49. Heath DJ, Chantry AD, Buckle CH, et al.: Inhibiting dickkopf-1 (Dkk1) removes suppression of bone formation and prevents the development of osteolytic bone disease in multiple myeloma. J Bone Miner Res 2008 Nov 18 (Epub ahead of print).
50. Yaccoby S, Ling W, Zhan F, et al.: Antibody-based inhibition of DKK1 suppresses tumor-induced bone resorption and multiple myeloma growth in vivo. Blood 2007, 109:2106-2111.